Immunoglobulin prophylaxis in hematopoietic stem cell transplantation: Systematic review and meta-analysis

Journal of Clinical Oncology

Volumn 27, Issue 5, 2009, Pages 770-781

  Raanani, Pia ^a   Gafter Gvili, Anat ^a   Paul, Mical ^a   Ben Bassat, Isaac ^a   Leibovici, Leonard ^a   Shpilberg, Ofer ^a  

^a TEL AVIV UNIVERSITY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ANTIBIOTIC AGENT; CEFTAZIDIME; CIPROFLOXACIN; COTRIMOXAZOLE; CYCLOSPORIN; CYTOMEGALOVIRUS ANTIBODY; FLUCONAZOLE; GANCICLOVIR; GLOBULIN; IMMUNOGLOBULIN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; IMMUNOTOXIN; METHOTREXATE; NORFLOXACIN; NYSTATIN; PLACEBO; POLYENE; POLYMYXIN; POLYVALENT IMMUNOGLOBULIN; QUINOLONE DERIVATIVE; SEVIRUMAB; STEROID; UNCLASSIFIED DRUG; VANCOMYCIN;

ACUTE LEUKEMIA; BACTERIAL INFECTION; BONE MARROW TRANSPLANTATION; CANCER SURVIVAL; CARDIOVASCULAR RISK; CHILL; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; CYTOMEGALOVIRUS INFECTION; DRUG DOSE COMPARISON; DRUG INDUCED HEADACHE; FEVER; GRAFT SURVIVAL; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HYPOTENSION; IMMUNOPROPHYLAXIS; INFECTION PREVENTION; INTERSTITIAL PNEUMONIA; META ANALYSIS; MORTALITY; MYALGIA; MYCOSIS; NAUSEA AND VOMITING; NEUTROPENIA; PRIORITY JOURNAL; RASH; REFERENCE DATABASE; REVIEW; RISK ASSESSMENT; RISK FACTOR; SYSTEMATIC REVIEW; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; VEIN OCCLUSION;

EID: 59949103959     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2008.16.8450     Document Type: Review

References (78)

1. Winston D J, Ho WG, Lin CH, et al: Intravenous immunoglobulin for modification of cytomegalovirus infections associated with bone marrow transplantation: Preliminary results of a controlled trial. Am J Med 76:128-133, 1984
2. Sullivan KM, Kopecky K J, Jocom J, et al: Immunomodulatory and antimicrobial efficacy of intravenous immunoglobulin in bone marrow transplantation. N Engl J Med 323:705-712, 1990
3. Filipovich AH, Peltier MH, Bechtel MK, et al: Circulating cytomegalovirus (CMV) neutralizing activity in bone marrow transplant recipients: Comparison of passive immunity in a randomized study of four intravenous IgG products administered to CMV-seronegative patients. Blood 80:2656-2660, 1992
4. Poynton CH, Jackson S, Fegan C, et al: Use of IgM enriched intravenous immunoglobulin (Penta- globin) in bone marrow transplantation. Bone Marrow Transplant 9:451-457, 1992
5. Winston D J, Ho WG, Bartoni K, et al: Ganci- clovir prophylaxis of cytomegalovirus infection and disease in allogeneic bone marrow transplant recipients: Results of a placebo-controlled, double-blind trial. Ann Intern Med 118:179-184, 1993
6. Condie R M, O'Reilly R J: Prevention of cytomegalovirus infection by prophylaxis with an intravenous, hyperimmune, native, unmodified cytomegalovirus globulin: Randomized trial in bone marrow transplant recipients. Am J Med 76:134-141,1984
7. Bowden RA, Sayers M, Flournoy N, et al: Cytomegalovirus immune globulin and seronegative blood products to prevent primary cytomegalovirus infection after marrow transplantation. N Engl J Med 314:1006-1010, 1986
8. Petersen FB, Bowden RA, Thornquist M, et al: The effect of prophylactic intravenous immune globulin on the incidence of septicemia in marrow transplant recipients. Bone Marrow Transplant 2:141-147, 1987
9. Winston D J, Ho WG, Lin CH, et al: Intravenous immune globulin for prevention of cytomega- lovirus infection and interstitial pneumonia after bone marrow transplantation. Ann Intern Med 106:12-18, 1987
10. Graham-Pole J, Camitta B, Casper J, et al: Intravenous immunoglobulin may lessen all forms of infection in patients receiving allogeneic bone marrow transplantation for acute lymphoblastic leukemia: A pediatric oncology group study. Bone Marrow Transplant 3:559-566, 1988
11. Consensus on IVIG. Lancet 336:470-472,1990
12. Winston D J, Antin JH, Wolff SN, et al: A multicenter, randomized, double-blind comparison of different doses of intravenous immunoglobulin for prevention of graft- versus- host disease and in- fection after allogeneic bone marrow transplantation. Bone Marrow Transplant 28:187-196, 2001
13. Bass EB, Powe NR, Goodman SN, et al: Efficacy of immune globulin in preventing complications of bone marrow transplantation: A meta- analysis. Bone Marrow Transplant 12:273-282, 1993
14. Glowacki L S, Smaill F M: Meta-analysis of immune globulin prophylaxis in transplant recipients for the prevention of symptomatic cytomegalovirus disease. Transplant Proc 25:1408-1410, 1993
15. Cordonnier C, Chevret S, Legrand M, et al: Should immunoglobulin therapy be used in alloge- neic stem-cell transplantation? A randomized, double-blind, dose effect, placebo-controlled, multi-center trial. Ann Intern Med 139:8-18, 2003
16. Higgins JPT, Green S: Cochrane Handbook for Systematic Reviews of Interventions 4.2.6 [updated September 2006]. Chichester, United Kingdom, John Wiley & Sons, Ltd, 2006
17. Juni P, Witschi A, Bloch R, et al: The hazards of scoring the quality of clinical trials for meta- analysis. JAMA 282:1054-1060, 1999
18. Winston D J, Pollard RB, Ho WG, et al: Cyto-megalovirus immune plasma in bone marrow transplant recipients. Ann Intern Med 97:11-18, 1982
19. Meyers J D, Leszczynski J, Zaia JA, et al: Prevention of cytomegalovirus infection by cyto- megalovirus immune globulin after marrow transplantation. Ann Intern Med 98:442-446, 1983
20. Jacobsen N, Schafer U, Ostendorf P, et al: Intravenous hyperimmune globulin prophylaxis against cytomegalovirus interstitial pneumonitis after allogenic bone marrow transplantation. Tokai J Exp Clin Med 10:193-195, 1985
21. Ringden O, Pihlstedt P, Volin L, et al: Failure to prevent cytomegalovirus infection by cytomegalovi- rus hyperimmune plasma: A randomized trial by the Nordic Bone Marrow Transplantation Group. Bone Marrow Transplant 2:299-305, 1987
22. Bordigoni P, Janot C, Aymard JP, et al: Clinical and biological evaluation of the preventive role of anti-cytomegalovirus specific immunoglobulins in bone marrow grafts: Randomized study of 60 patients [in French]. Nouv Rev Fr Hematol 29:289-293,1987
23. Bowden RA, Fisher LD, Rogers K, et al: Cyto-megalovirus (CMV)-specific intravenous immuno- globulin for the prevention of primary CMV infection and disease after marrow transplant. J Infect Dis 164:483-487, 1991
24. Peltier M K, Filipovich AH, Bechtel M, et al: Randomized double-blinded comparison of three intravenous immunoglobulin products in bone marrow transplantation. Semin Hematol 29:112-115,1992
25. Emanuel D, Taylor J, Brochstein J, et al: The use of intravenous immune globulin as prophylaxis for the infectious complications of allogeneic marrow transplantation. Blood 80:271a, 1992 (suppl 1;abstr 1075)
26. Winston D J, Ho WG, Bartoni K, et al: Intravenous immunoglobulin and CMV- seronegative blood products for prevention of CMV infection and disease in bone marrow transplant recipients. Bone Marrow Transplant 12:283-288, 1993
27. Lum L, Bitonti O, Jin NR, et al: Intravenous gamma-globulin (Ivig) does not alter immune parameters in a randomized trial after bone marrow transplantation. Exp Hematol 22:680, 1994
28. Wolff S, Winston D, Antin J, et al: Multi center randomized double-blind dose response trial of IVIG for the prevention of infection after allogeneic bone marrow transplantation. Blood 88:303a, 1996
29. Ruutu T, Ljungman P, Brinch L, et al: No prevention of cytomegalovirus infection by anti- cytomegalovirus hyperimmune globulin in seroneg- ative bone marrow transplant recipients: The Nordic BMT Group. Bone Marrow Transplant 19:233-236, 1997
30. Zikos P, Van Lint MT, Lamparelli T, et al: A randomized trial of high dose polyvalent intravenous immunoglobulin (HDIgG) vs. cytomegalovirus (CMV) hyperimmune IgG in allogeneic hemopoietic stem cell transplants (HSCT). Haematologica 83:132-137,1998
31. Ustun C, Ozcan M, Beksac M, et al: Clinical effects of intravenous immune globulin (IVIG) treatment in patients with allogeneic peripheral stem cell transplantation. Blood 92:355b, 1998
32. Serrano J, Falcon M, Castillejo J A, et al: A randomized trial to determine the utility of intravenous hyperimmune immunoglobulin in antimicrobial prophylaxis and its immunomodulatory effect in allogeneic bone marrow transplantation. Transplan- tology 10:1-10, 1999
33. Abdel-Mageed A, Graham-Pole J, Del Rosario ML, et al: Comparison of two doses of intravenous immunoglobulin after allogeneic bone marrow transplants. Bone Marrow Transplant 23:929-932, 1999
34. Feinstein LC, Seidel K, Jocum J, et al: Reduced dose intravenous immunoglobulin does not decrease transplant-related complications in adults given related donor marrow allografts. Biol Blood Marrow Transplant 5:369-378, 1999
35. Sullivan KM, Seidel K, Jocom J, et al: Intravenous immunoglobulin (IVIG) prophylaxis in unrelated donor bone marrow transplantation (BMT): A phase III double-blind, placebo-controlled multi-institutional trial. Proc Am Soc Clin Oncol 19:47a, 2000 (abstr 181)
36. Boeckh M, Bowden RA, Storer B, et al: Randomized, placebo-controlled, double-blind study of a cytomegalovirus-specific monoclonal antibody (MSL-109) for prevention of cytomegalovirus infection after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 7:343-351,2001
37. Raiola AM, Di Grazia C, Dominietto A, et al: Prevention of graft versus host disease with IgM enriched immunoglobulins: A preliminary analysis of a randomized study. Bone Marrow Transplant 29: S188, 2002
38. Wolff SN, Fay JW, Herzig RH, et al: High-dose weekly intravenous immunoglobulin to prevent infections in patients undergoing autologous bone marrow transplantation or severe myelosuppressive therapy: A study of the American Bone Marrow Transplant Group. Ann Intern Med 118:937-942, 1993
39. Terada H, Matsuno K: Clinical effects of gamma globulin in severe infections associated with leukemia and malignant lymphoma [in Japanese]. Rinsho Ketsueki 21:1328-1332, 1980
40. Vu Van H, Fiere D, Chomel J, et al: Prophylaxis against cytomegalovirus infection after BMT with gammaglobulins. Exp Hematol 13:105, 1985
41. Nurnberger W, Willers R, Schroten H, et al: Preventive long-term intravenous immunoglobulin infusion in children with acute lymphatic leukemia. II. Zymosan opsonization is decreased and is not increased by IgG infusions [in German]. Monatsschr Kinderheilkd 136:181-185, 1988
42. Bunch C: Immunoglobulin replacement in chronic lymphocytic leukaemia [in French]. Nouv Rev Fr Hematol 30:419-422, 1988
43. Gerein V, Kropp H, Schwabe D, et al: Prevention of cytomegalic inclusion disease in leukemia patients with a cytomegalovirus hyperimmune globulin preparation [in German]. Klin Padiatr 201:322-329, 1989
44. Fehir KM, Decker WA, Samo T, et al: Immune globulin (Gammagard) prophylaxis of CMV infections in patients undergoing organ transplantation and allogeneic bone marrow transplantation. Transplant Proc 21:3107-3109, 1989
45. Elfenbein G, Krischer J, Babington R, et al: Interim results of a multicenter trial to prevent cytomegalovirus pneumonia after allogeneic bone marrow transplantation. Transplant Proc 21:3099-3100, 1989
46. Rand KH, Gibbs K, Derendorf H, et al: Phar- macokinetics of intravenous immunoglobulin (Gam- magard) in bone marrow transplant patients. J Clin Pharmacol 31:1151-1154, 1991
47. Aulitzky WE, Schulz TF, Tilg H, et al: Human monoclonal antibodies neutralizing cytomegalovirus (CMV) for prophylaxis of CMV disease: Report of a phase I trial in bone marrow transplant recipients. J Infect Dis 163:1344-1347, 1991
48. Spitzer TR, Cottler-Fox M, Sullivan P, et al: Continuous infusion intravenous immunoglobulin is associated with a reduced incidence of infection and achieves higher serum immunoglobulin G levels than intermittent infusion following bone marrow transplantation. Semin Hematol 29:123-126, 1992
49. Chapel HM, Lee M: Immunoglobulin replacement in patients with chronic lymphocytic leukemia (CLL): Kinetics of immunoglobulin metabolism. J Clin Immunol 12:17-20, 1992
50. Chapel HM, Hargreaves R, Lee M, et al: Intravenous immunoglobulin therapy in patients with multiple myeloma. Immunodeficiency 4:77-78, 1993
51. Messori A, Rampazzo R, Scroccaro G, et al: Efficacy of hyperimmune anti-cytomegalovirus im- munoglobulins for the prevention of cytomegalovi- rus infection in recipients of allogeneic bone marrow transplantation: A meta-analysis. Bone Marrow Transplant 13:163-167, 1994
52. Jurlander J, Geisler CH, Hansen MM: Treatment of hypogammaglobulinaemia in chronic lym- phocytic leukaemia by low-dose intravenous gammaglobulin. Eur J Haematol 53:114-118, 1994
53. Gamm H, Huber C, Chapel H, et al: Intravenous immune globulin in chronic lymphocytic leukaemia. Clin Exp Immunol 97:17-20, 1994 (suppl 1)
54. Klaesson S, Ringden O, Markling L, et al: Intravenous immunoglobulin: Immune modulatory effects in vitro and clinical effects in allogeneic bone marrow transplant recipients. Transplant Proc 27:3536-3537, 1995
55. Sullivan KM, Storek J, Kopecky KJ, et al: A controlled trial of long-term administration of intravenous immunoglobulin to prevent late infection and chronic graft-vs.-host disease after marrow transplantation: Clinical outcome and effect on subsequent immune recovery. Biol Blood Marrow Transplant 2:44-53, 1996
56. Sullivan KM, Kansu E, Storer B, et al: Intravenous immunoglobulin and the risk of hepatic veno-occlusive disease after bone marrow transplantation. Biol Blood Marrow Transplant 4:20-26, 1998
57. Nasman Bjork I, Fesel C, Brissac C, et al: Prophylactic intravenous immunoglobulin treatment influences serum immunoglobulin M repertoire development after allogeneic bone marrow transplantation. Scand J Immunol 50:73-82, 1999
58. Esperou H, Brunot A, Cordonnier C, et al: Influence of baseline status and of transplant-related complications on the costs of allogeneic sibling stem cell transplantation: Results from a randomized multi-center French immunoglobulin trial. Blood 98:5151, 2001
59. Cortez K, Murphy BR, Almeida KN, et al: Immune-globulin prophylaxis of respiratory syncytial virus infection in patients undergoing stem-cell transplantation. J Infect Dis 186:834-838, 2002
60. Bode U, Erps M, Liappis N: Immunoglobulin administration as infection prevention in oncologic patients [in German]. Klin Padiatr 198:476-478, 1986
61. Collins PW, Slocombe G, Wainwright A, et al: A pilot study using intravenous immunoglobulin for the prevention of infection during remission induction in acute leukaemia. Leuk Lymphoma 6:25-30,1991
62. Gimesi A, Eibl M, Koos R, et al: Immunoglob- ulin prophylaxis during intensive treatment of acute lymphoblastic leukemia in children. Acta Paediatr Hung 32:115-125, 1992
63. Eijkhout HW, Der Meer JW, Kallenberg CG, et al: The effect of two different dosages of intravenous immunoglobulin on the incidence of recurrent infections in patients with primary hypogamma- globulinemia: A randomized, double-blind, multi- center crossover trial. Ann Intern Med 135:165-174,2001
64. Copelan EA, Bechtel TP, Klein JP, et al: Controlled trial of orally administered immunoglobulin following bone marrow transplantation. Bone Marrow Transplant 13:87-91, 1994
65. Salmon SE, Samal BA, Hayes DM, et al: Role of gamma globulin for immunoprophylaxis in multiple myeloma. N Engl J Med 277:1336-1340, 1967
66. Intravenous immunoglobulin for the prevention of infection in chronic lymphocytic leukemia: A randomized, controlled clinical trial: Cooperative Group for the Study of Immunoglobulin in Chronic Lymphocytic Leukemia. N Engl J Med 319:902-907,1988
67. Gluck S, Schnutenhaus W, Schneider W: Prophylactic intravenous immunoglobulin (IVIG) application to patients with recurrent infections and secondary antibody deficiency due to B-cell neoplasia [in German]. Blut 61:140, 1990
68. Hargreaves RM: Infection, immune responses and intravenous immunoglobulin infection prophylaxis in myeloma. Br J Cancer 66:11, 1992
69. Sklenar I, Schiffman G, Jonsson V, et al: Effect of various doses of intravenous polyclonal IgG on in vivo levels of 12 pneumococcal antibodies in patients with chronic lymphocytic leukaemia and multiple myeloma. Oncology 50:466-477, 1993
70. Chapel HM, Lee M, Hargreaves R, et al: Randomised trial of intravenous immunoglobulin as prophylaxis against infection in plateau-phase multiple myeloma: The UK Group for Immunoglobulin Replacement Therapy in Multiple Myeloma. Lancet 343:1059-1063, 1994
71. Boughton BJ, Jackson N, Lim S, et al: Randomized trial of intravenous immunoglobulin prophylaxis for patients with chronic lymphocytic leukaemia and secondary hypogammaglobulinae-mia. Clin Lab Haematol 17:75-80, 1995
72. Musto P, Brugiatelli M, Carotenuto M: Prophylaxis against infections with intravenous immu- noglobulins in multiple myeloma. Br J Haematol 89:945-946, 1995
73. Molica S, Musto P, Chiurazzi F, et al: Prophylaxis against infections with low-dose intravenous immunoglobulins (IVIG) in chronic lymphocytic leukemia: Results of a crossover study. Haematologica 81:121-126, 1996
74. O'Reilly RJ, Reich L, Gold J, et al: A randomized trial of intravenous hyperimmune globulin for the prevention of CMV infections following marrow transplantation: Preliminary results. Transplant Proc 15:1405-1411, 1983
75. Kubaneck B, Ernst P, Ostendorf P, et al: Preliminary data of a controlled trial of intravenous hyperimmune globulin in the prevention of cytomeg- alovirus infection in bone marrow transplant recipients. Transplant Proc 17:468-469, 1985
76. Winston DJ, Ho WG, Lin GH, et al: Use of a polyvalent intravenous immunoglobulin or specific cytomegalovirus hyperimmunoglobulin for modification of cytomegalovirus infections and prevention of interstitial pneumonias following bone marrow transplantation [in German]. Immunitat und Infektion 13:296-301, 1985
77. Griffiths H, Brennan V, Lea J, et al: Crossover study of immunoglobulin replacement therapy in patients with low-grade B-cell tumors. Blood 73: 366-368, 1989
78. Jackson SK, Parton J, Barnes RA, et al: Effect of IgM-enriched intravenous immunoglobulin (Pen- taglobin) on endotoxaemia and anti-endotoxin antibodies in bone marrow transplantation. Eur J Clin Invest 23:540-545, 1993